Ketamine Therapy for Neuropathic Pain
Neuropathic pain differs from ordinary pain because it originates from damage or dysfunction within the nervous system rather than ongoing tissue injury alone. Patients may describe burning, shooting, electric, tingling, or persistent aching sensations that can continue long after an injury has healed. These symptoms can interfere with sleep, mobility, work, and everyday functioning, and some patients continue to experience significant pain despite established treatment approaches. Neuropathic pain ketamine therapy may be considered for selected adults when appropriate first line treatments have not provided adequate relief.
Allay Health & Wellness offers neuropathic pain ketamine therapy in Palm Beach Gardens, Florida, strictly as an off label clinical service following an individualized medical evaluation. IV ketamine is not FDA approved for neuropathic pain or any chronic pain condition, and treatment outcomes cannot be guaranteed. This page explains how neuropathic pain differs from nociceptive pain, established treatment options, current ketamine research, potential risks and limitations, and the clinical factors considered when determining whether neuropathic pain ketamine therapy may be appropriate.
What Neuropathic Pain Is
Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. This distinguishes it from nociceptive pain, which is the normal protective response to tissue damage. In nociceptive pain, the pain system is functioning properly: tissue is damaged, nociceptors fire, and the brain registers the pain as a signal to protect the injured area.
In neuropathic pain, the pain system itself is damaged or dysfunctional. The nerves that carry pain signals are generating those signals spontaneously, amplifying them, or misfiring in response to stimuli that should not be painful at all. The pain is not a signal about tissue. It is a malfunction of the signaling system. The National Institute of Neurological Disorders and Stroke identifies neuropathic pain as a complex, chronic pain state associated with multiple conditions. Common causes include diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, complex regional pain syndrome, spinal cord injury, post surgical nerve damage, and trigeminal neuralgia. Each involves nerve damage by different mechanisms, but all share the characteristic that pain is generated by the nervous system itself rather than by ongoing tissue injury.
At Allay Health & Wellness, our approach to chronic pain includes a range of persistent pain conditions, including neuropathic presentations. Because chronic neuropathic pain can also occur alongside depression or anxiety, these symptoms should be evaluated as part of the broader clinical picture. Patients experiencing significant depressive symptoms can discuss whether ketamine therapy for depression may be appropriate based on their individual history, while those living with persistent anxiety can separately explore the potential role of ketamine therapy for anxiety within a coordinated treatment plan.
Why Neuropathic Pain Is Difficult to Treat
Neuropathic pain is notoriously resistant to standard analgesics. Over the counter pain medications including NSAIDs and acetaminophen have limited effectiveness for most neuropathic pain presentations, because the mechanism driving the pain is not inflammation or peripheral nociception. The FDA approved first line medications for neuropathic pain include gabapentinoids such as gabapentin and pregabalin, tricyclic antidepressants such as amitriptyline and nortriptyline, and SNRIs such as duloxetine and venlafaxine. These are effective for a meaningful proportion of patients but leave a substantial portion with inadequate relief, or with relief that is incomplete and accompanied by significant side effects including sedation, cognitive effects, weight gain, and balance problems.
Topical treatments including lidocaine patches and capsaicin preparations have evidence for localized presentations. Opioids can provide partial relief but are generally not recommended as first line treatment for neuropathic pain due to limited long term evidence, dependence risk, and the observation that many neuropathic conditions respond poorly to opioid analgesia.
When multiple first line and second line medications have been tried without adequate relief, the clinical conversation shifts. This is precisely where neuropathic pain ketamine therapy enters as a clinically rational option, and where neuropathic pain ketamine therapy has a stronger mechanistic argument than most off label treatments.
Why Ketamine’s Mechanism Is Directly Relevant to Neuropathic Pain
This is the section that distinguishes neuropathic pain ketamine therapy from most other off label applications of ketamine, because the mechanistic connection is particularly strong. Ketamine is a potent NMDA receptor antagonist. NMDA receptors play a central role in central sensitization, the process by which the central nervous system becomes amplified in its processing of pain. In neuropathic pain, central sensitization is a core feature, not an incidental complication. The damaged or dysfunctional peripheral nerves generate abnormal input that drives the spinal cord and brain into a sensitized state, and that central sensitization is what produces many of the most distressing features of neuropathic pain: allodynia, in which light touch becomes painful, hyperalgesia, in which painful stimuli become more painful than they should be, and spontaneous pain in the absence of any triggering stimulus.
By blocking NMDA receptors, ketamine directly addresses one of the primary mechanisms maintaining central sensitization. This is not a peripheral mechanism. It is central, which is exactly where neuropathic pain is generated. The neurobiological mechanism is explored further in how ketamine for anxiety works. Standard gabapentinoids reduce calcium channel mediated neurotransmitter release. SNRIs modulate descending pain inhibitory pathways. For patients who have not responded to either, ketamine’s NMDA antagonism is a genuinely different mechanism rather than another variation of what has already failed.
What the Evidence Shows for Neuropathic Pain Ketamine Therapy
The evidence base for neuropathic pain ketamine therapy is more developed than for many other off label ketamine applications, but important limitations remain. Research includes randomized controlled trials across several neuropathic pain conditions, with differences in study size, dosing protocols, treatment duration, and reported outcomes.
Evidence From Clinical Studies
Multiple small to medium sized randomized controlled trials have examined IV ketamine for neuropathic pain. A 2011 Cochrane review found evidence of an analgesic effect but also noted substantial heterogeneity across available studies. Subsequent research has examined ketamine in conditions including complex regional pain syndrome (CRPS), diabetic neuropathy, and chemotherapy induced peripheral neuropathy. These findings provide a clinical rationale for continued investigation but do not establish consistent effectiveness across neuropathic pain conditions.
Research on Complex Regional Pain Syndrome
Among neuropathic pain conditions, CRPS has received considerable attention in ketamine research. A review published in Pain Medicine examined IV ketamine infusion studies in patients with CRPS and reported reductions in pain in several studies, with some studies describing effects that persisted beyond the infusion period. However, differences in protocols, patient populations, and study designs make it difficult to predict how an individual patient will respond.
Ketamine in Clinical Pain Management
The American Chronic Pain Association resource cited here discusses ketamine’s use for neuropathic pain and the developing evidence surrounding treatment for refractory pain. Clinical oversight remains particularly important because ketamine is used off label for these pain conditions and carries potential risks and side effects.
What the Evidence Does Not Establish
Neuropathic pain ketamine therapy is not established as standard care for every neuropathic pain diagnosis. Available studies are generally limited in size, treatment protocols vary, and the duration of any benefit differs across conditions and patients. Current research provides a rationale for considering ketamine in selected patients with refractory neuropathic pain after established treatments have been inadequate, but it does not support describing the treatment as proven, universally effective, or appropriate for everyone.
FDA Approval and Off Label Ketamine Use for Neuropathic Pain
Neuropathic pain ketamine therapy is an off label use. The FDA has not approved IV ketamine for any pain condition, including neuropathic pain. Ketamine’s only FDA approved indication is as a general anesthetic.
Spravato (esketamine) is not approved for any pain condition. Its approved indications are treatment resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is not used at Allay Health and Wellness for pain. Off label prescribing by a licensed clinician is legal and routine across medicine. Many neuropathic pain treatments, including antidepressants and anticonvulsants, were used off label before the evidence caught up with clinical practice. Neuropathic pain ketamine therapy is in a similar position: mechanism compelling, evidence encouraging, regulatory status not yet caught up with clinical use.
Neuropathic Pain, Mood, and the Bidirectional Relationship
Chronic neuropathic pain and mood disorders co occur at rates substantially higher than chance, and the relationship runs in both directions. Chronic pain drives depression and anxiety through disrupted sleep, loss of function, and shared neurobiological pathways. Depression and anxiety in turn amplify pain perception through increased central sensitization, reduced descending pain inhibition, and catastrophizing, itself a predictor of pain intensity and disability. This bidirectional relationship matters for neuropathic pain ketamine therapy in a practical way. Ketamine has documented antidepressant and anxiolytic effects alongside its analgesic effects. For a patient with comorbid depression, the overall pain reduction may exceed what NMDA blockade alone would predict, because improved mood reduces central sensitization independently.
Daniel Cartledge, M.D., our clinical consultant, is double board certified in pain management and physical medicine and rehabilitation. His clinical background is specifically relevant for patients with complex neuropathic pain presentations where pain, function, and psychiatric health are intertwined.
What Neuropathic Pain Ketamine Therapy Involves at Allay
Every patient considering neuropathic pain ketamine therapy at Allay Health & Wellness begins with a clinical evaluation before treatment is recommended. The process includes reviewing your pain history and previous care, discussing what infusion treatment involves, monitoring you during each session, and providing clear instructions for aftercare.
- Evaluation: Intake covers your pain diagnosis and history, the identified cause of your neuropathic pain when known, medications previously tried with doses and durations, current pain management regimen, co-occurring psychiatric conditions, cardiovascular health, and substance use history, including opioid use. No referral is required. Bringing your complete clinical record can support a more informed evaluation.
- The Sessions: IV ketamine is administered slowly through an intravenous line in a private, monitored room. A licensed clinician monitors vital signs throughout each session. Pain protocols may involve longer infusion durations than psychiatric protocols. For neuropathic pain ketamine therapy, the number, duration, and frequency of infusions are determined according to your clinical presentation and response. During consultation, we also discuss how many ketamine therapy sessions may be needed and why treatment schedules for chronic pain can differ from psychiatric protocols.
- After Sessions: You may not drive after an infusion. A responsible adult must arrange transportation home, and you should follow the individualized post treatment instructions provided by your clinical team.
Who May Be a Candidate
A clinical evaluation is required before any treatment recommendation at Allay. Adults who may be appropriate candidates for neuropathic pain ketamine therapy typically present with the following:
A documented neuropathic pain diagnosis with an identified underlying cause or a well characterized clinical presentation, with documented history of inadequate response to at least two first line neuropathic pain medications at adequate doses and durations. Active engagement with a comprehensive pain management approach including applicable physical therapy and psychological support alongside infusion treatment. Absence of medical contraindications including uncontrolled hypertension, unstable cardiovascular conditions, or active psychosis.
Substance use history is evaluated carefully because ketamine is a Schedule III controlled substance. In a chronic pain population where opioid use is common, this is handled carefully during intake. Allay Health and Wellness treats adult patients 18 years and older exclusively.
Potential Risks and Side Effects of Neuropathic Pain Ketamine Therapy
Every patient evaluated for neuropathic pain ketamine therapy receives a clear explanation of potential risks, side effects, and treatment limitations before anything is scheduled. Dissociation can cause temporary changes in perception, awareness, time, space, or sense of self and is monitored throughout every infusion. Sedation can also occur, which means patients may not drive after treatment and must arrange transportation home.
Temporary increases in blood pressure and heart rate can occur and are monitored before, during, and after treatment. Nausea may occur during longer pain management infusions, and clinicians may consider anti nausea medication based on individual history and clinical judgment. Some patients also experience vivid perceptual or emotional changes, with clinical staff remaining present throughout treatment.
Ketamine is a federally regulated Schedule III controlled substance, so dependency and misuse risks remain part of ongoing clinical assessment. Understanding whether ketamine can be addictive is particularly relevant when repeated treatment is considered for chronic pain. No outcome from neuropathic pain ketamine therapy is guaranteed, and individual responses can vary considerably.
FAQs about Neuropathic Pain Ketamine Therapy
- Is ketamine FDA-approved for neuropathic pain?
No. Neuropathic pain ketamine therapy is an off-label use. The FDA has not approved IV ketamine for neuropathic pain or any pain condition. Established treatments, including medications such as gabapentin, pregabalin, duloxetine, and certain topical agents, are generally considered before off-label options. - Why might ketamine be considered when other neuropathic pain medications have not helped?
Common neuropathic pain medications work through mechanisms such as calcium channel modulation or monoamine reuptake inhibition. Ketamine acts differently through NMDA receptor antagonism, a mechanism involved in pain processing and central sensitization. This provides a clinical rationale for considering ketamine in selected patients, although individual benefit cannot be predicted. - How long does neuropathic pain ketamine therapy take to work?
Treatment response varies considerably. Some patients may notice changes in pain during or after an infusion course, while others may notice changes later or experience no meaningful improvement. No specific response or timeline can be predicted before treatment begins. - Does neuropathic pain ketamine therapy need to be repeated?
The duration of any response varies between patients. Some may experience a period of symptom improvement after an initial course, while others may have limited or no benefit. Any decision about additional or maintenance infusions is based on individual clinical response and ongoing evaluation. - Does insurance cover neuropathic pain ketamine therapy?
Off-label IV ketamine is generally not covered by most insurance plans. Allay Health & Wellness accepts Medicare, Cigna, UnitedHealthcare, and Aetna for eligible services. Our team verifies available benefits and provides anticipated cost information before treatment is scheduled. Coverage varies by plan and is never guaranteed. - Do I need a referral?
No referral is required. Bring available documentation of your pain diagnosis, medications previously tried with doses and durations, current pain management regimen, and relevant imaging, nerve conduction studies, or specialist notes.
Schedule a Consultation for Neuropathic Pain Ketamine Therapy
If established treatments have not provided adequate improvement for your neuropathic pain, Allay Health & Wellness is available to discuss whether neuropathic pain ketamine therapy may be appropriate for your individual situation. Our clinical team evaluates your medical history, previous treatments, current medications, and treatment goals while providing realistic information about potential risks, limitations, and available evidence.
Before making a decision, you can learn more about the clinicians involved in your care and review the peer reviewed research that informs our approach. Patients managing other persistent pain conditions can also explore how ketamine for chronic pain fits within the broader range of conditions we evaluate. Allay Health & Wellness treats adults aged 18 and older exclusively.
Our Location
7340 Southwest 90th Street
Miami, FL 33156
Phone Number
+1 (786) 885-3425
Email Us
[email protected]
Contact Allay Health & Wellness to schedule a consultation and discuss your treatment options with our clinical team.
Medical Disclaimer: This content is educational only and not a substitute for professional medical advice. IV ketamine for neuropathic pain is an off-label use, not FDA-approved for any pain condition. Spravato is not approved for pain. First-line medications should be tried before off-label options. Evidence for ketamine in neuropathic pain is encouraging but limited in large-scale trials. Outcomes vary and are never guaranteed. Treatment requires evaluation by a licensed clinician. Allay Health treats adults 18 and older.
Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness
